By Karen Roman
Agendia, Inc. said it will present MammaPrint’s ability to predict chemotherapy benefit in patients with early-stage breast cancer at the San Antonio Breast Cancer Symposium 2024.
“This study highlights the ability of MammaPrint to provide a comprehensive understanding of how the biology of a patient’s tumor greatly impacts treatment decisions, and we are thrilled to be at the forefront of these advancements,” said William Audeh, Agendia’s Chief Medical Officer.
Contact:
